DE60036534D1 - Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung - Google Patents

Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung

Info

Publication number
DE60036534D1
DE60036534D1 DE60036534T DE60036534T DE60036534D1 DE 60036534 D1 DE60036534 D1 DE 60036534D1 DE 60036534 T DE60036534 T DE 60036534T DE 60036534 T DE60036534 T DE 60036534T DE 60036534 D1 DE60036534 D1 DE 60036534D1
Authority
DE
Germany
Prior art keywords
therapeutic agent
solid pharmaceutical
cyclodextrin
sulfoal
cyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036534T
Other languages
English (en)
Other versions
DE60036534T2 (de
Inventor
Valentino J Stella
Roger A Rajewski
Venkatramana M Rao
James W Mcginity
Gerold L Mosher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cydex Pharmaceuticals Inc
Original Assignee
Cydex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Inc filed Critical Cydex Inc
Application granted granted Critical
Publication of DE60036534D1 publication Critical patent/DE60036534D1/de
Publication of DE60036534T2 publication Critical patent/DE60036534T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
DE60036534T 1999-01-13 2000-01-11 Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung Expired - Lifetime DE60036534T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/229,513 US6046177A (en) 1997-05-05 1999-01-13 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US229513 1999-01-13
PCT/US2000/000640 WO2000041704A1 (en) 1999-01-13 2000-01-11 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations

Publications (2)

Publication Number Publication Date
DE60036534D1 true DE60036534D1 (de) 2007-11-08
DE60036534T2 DE60036534T2 (de) 2009-01-29

Family

ID=22861562

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036534T Expired - Lifetime DE60036534T2 (de) 1999-01-13 2000-01-11 Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung

Country Status (17)

Country Link
US (1) US6046177A (de)
EP (4) EP1859790A3 (de)
JP (2) JP2002534472A (de)
KR (2) KR100712941B1 (de)
CN (1) CN1202833C (de)
AT (1) ATE374017T1 (de)
AU (1) AU758376B2 (de)
CA (1) CA2360236C (de)
DE (1) DE60036534T2 (de)
ES (1) ES2290012T3 (de)
HK (1) HK1049797A1 (de)
IL (2) IL143900A0 (de)
MX (1) MXPA01007122A (de)
NZ (1) NZ512692A (de)
PT (1) PT1140960E (de)
RU (1) RU2233176C9 (de)
WO (1) WO2000041704A1 (de)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638508B2 (en) 1995-12-21 2003-10-28 Yeda Research And Development Co., Ltd. Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6248361B1 (en) * 1999-02-26 2001-06-19 Integ, Ltd. Water-soluble folic acid compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
ATE416791T1 (de) * 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
EP1286663B1 (de) * 2000-05-18 2006-01-18 Therics, Inc. Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
WO2002032459A2 (en) * 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
US6753083B2 (en) * 2000-11-06 2004-06-22 Ciba Specialty Chemicals Water Treatments Ltd. Particles
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
US20020119196A1 (en) * 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
WO2002055562A2 (en) * 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
DE10106446A1 (de) * 2001-02-09 2002-10-10 Haarmann & Reimer Gmbh Verfahren zur Herstellung blauer Mikrokapseln
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
KR20040100835A (ko) * 2001-02-15 2004-12-02 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
EP1269994A3 (de) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
US20030138403A1 (en) * 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
CA2452364A1 (en) * 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
EP2957281A1 (de) 2001-09-21 2015-12-23 Egalet Ltd. Polymer-freigabe-system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
AU2002341959A1 (en) * 2001-10-04 2003-04-14 Case Western Reserve University Drug delivery devices and methods
US20030190350A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
EA008072B1 (ru) * 2001-12-03 2007-02-27 Новацея, Инк. Фармацевтические составы, содержащие соединения активного витамина d
NZ526926A (en) * 2001-12-19 2006-02-24 Astrazeneca Ab New film coating composition that provides a latex dispersion for coating pharmaceutical formulations
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
MXPA04008171A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulacion oftalmica con sistema de goma.
MXPA04008173A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US6824763B2 (en) 2002-05-30 2004-11-30 Kimberly-Clark Worldwide, Inc. Anti-fungal powder having enhanced excipient properties
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
BR0316685A (pt) * 2002-12-17 2005-11-01 Nastech Pharm Co Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
KR100473422B1 (ko) * 2003-06-12 2005-03-14 박원봉 렉틴 함유 천연물의 장용성 코팅용 조성물
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050186276A1 (en) * 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
US20070190129A1 (en) * 2003-09-02 2007-08-16 Pfizer Inc. Sustained release dosage forms of ziprasidone
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
KR20070007076A (ko) * 2003-12-31 2007-01-12 사이덱스 인크 술포알킬 에테르 γ-시클로덱스트린 및코르티코스테로이드를 함유한 흡입용 제형
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CN100393859C (zh) * 2004-04-05 2008-06-11 新疆芳香植物科技开发股份有限公司 芳香类植物精油的微胶囊及其制备方法
CA2562411A1 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
KR101781166B1 (ko) 2004-04-23 2017-09-22 사이덱스 파마슈티칼스, 인크. 술포알킬 에테르 시클로덱스트린 함유 분말의 제조 방법 및 그 분말
EP2564834A3 (de) * 2004-05-10 2013-08-21 Onyx Therapeutics, Inc. Verbindungen zur Proteasomenzyminhibition
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
MX2007000759A (es) * 2004-07-22 2007-03-28 Pfizer Prod Inc Formulacion de enmascaramiento del sabor que comprende el farmaco en una forma de disolucion retardada y/o ciclodextrina en una forma de disolucion mejorada.
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1789022A2 (de) * 2004-08-31 2007-05-30 Pfizer Products Incorporated Kontrollierte dosierungsfreisetzungsformen, die die sofortige freisetzung und die verzögerte freisetzung eines arzneimittels mit geringer löslichkeit kombinieren
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
EP2260835B1 (de) * 2004-12-07 2013-03-06 Onyx Therapeutics, Inc. Zusammensetzung zur Proteasomhemmung
JP2006182679A (ja) * 2004-12-27 2006-07-13 Daicho Kikaku:Kk ストレス性胃炎予防・治療剤
CA2600282A1 (en) * 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
DE102005028168B3 (de) * 2005-06-17 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Einrichtung zur Führung eines Gases für Vorrichtungen zum Behandeln körnigen Gutes durch Trocknen, Filmcoaten oder Beschichten, insbesondere Zulufteinheit und Vorrichtung mit einer derartigen Einrichtung
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
PT1928464E (pt) * 2005-09-30 2014-07-10 Lundbeck Inc Nova formulação parentérica de carbamazepina
US7629331B2 (en) * 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PL2581078T3 (pl) 2005-10-26 2015-07-31 Cydex Pharmaceuticals Inc Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
WO2007053684A2 (en) * 2005-11-01 2007-05-10 University Of Kansas Neuroprotective agents
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
PL2623113T3 (pl) * 2005-11-09 2018-05-30 Onyx Therapeutics, Inc. Związek do hamowania enzymu
JP5159094B2 (ja) * 2005-11-11 2013-03-06 旭化成ケミカルズ株式会社 活性成分の溶出を徐放性に制御する有核固形製剤
JP5159095B2 (ja) * 2005-11-11 2013-03-06 旭化成ケミカルズ株式会社 活性成分の溶出を徐放性に制御する固形製剤
JP5159092B2 (ja) * 2005-11-11 2013-03-06 旭化成ケミカルズ株式会社 活性成分の溶出を徐放性に制御する固形製剤
JP5159093B2 (ja) * 2005-11-11 2013-03-06 旭化成ケミカルズ株式会社 活性成分の溶出を徐放性に制御する多層固形製剤
JP5159091B2 (ja) * 2005-11-11 2013-03-06 旭化成ケミカルズ株式会社 活性成分の溶出を徐放性に制御する固形製剤
US8685478B2 (en) 2005-11-21 2014-04-01 Philip Morris Usa Inc. Flavor pouch
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
US20070197487A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an increased lung deposition
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
EP2010162A4 (de) * 2006-04-03 2013-01-09 Isa Odidi Zusammensetzung zur abgabe eines arzneimittels
JP2007308479A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
BRPI0713309A2 (pt) 2006-06-19 2012-04-17 Proteolix Inc compostos para inibição de enzimas
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
ES2532084T3 (es) * 2006-09-15 2015-03-24 Regents Of The University Of Minnesota Composiciones de topiramato y métodos para su uso
CN100584319C (zh) * 2006-10-16 2010-01-27 北京科信必成医药科技发展有限公司 群孔释放渗透泵控释片及其制备方法
MX2009004214A (es) 2006-10-20 2009-05-11 Icos Corp Composiciones de inhibidores de chk1.
NZ581362A (en) 2007-04-27 2011-07-29 Cydex Pharmaceuticals Inc Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8124147B2 (en) * 2007-07-16 2012-02-28 Philip Morris Usa Inc. Oral pouch products with immobilized flavorant particles
US8424541B2 (en) 2007-07-16 2013-04-23 Philip Morris Usa Inc. Tobacco-free oral flavor delivery pouch product
MY166950A (en) 2007-10-04 2018-07-25 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US8040246B2 (en) * 2007-12-04 2011-10-18 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
JP2009256237A (ja) * 2008-04-16 2009-11-05 Daiichi Sankyo Healthcare Co Ltd 固形製剤
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US20100022635A1 (en) * 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
WO2010053487A1 (en) * 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
ES2607209T3 (es) 2009-02-06 2017-03-29 Egalet Ltd. Composiciones farmacéuticas resistentes al abuso
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
HUE047755T2 (hu) 2009-05-13 2020-05-28 Cydex Pharmaceuticals Inc Prasugrelt és ciklodextrin-származékokat tartalmazó gyógyszerkészítmények, eljárás ezek elõállítására és alkalmazásra
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
US20100311838A1 (en) 2009-05-29 2010-12-09 Pipkin James D Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
SI2442791T1 (sl) 2009-06-16 2020-03-31 Pfizer Inc. Dozirna oblika apiksabana
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
US8747562B2 (en) * 2009-10-09 2014-06-10 Philip Morris Usa Inc. Tobacco-free pouched product containing flavor beads providing immediate and long lasting flavor release
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
US20130203721A1 (en) 2010-02-22 2013-08-08 Lupin Limited Taste-masked powder for suspension compositions of methylprednisolone
EP2542238B1 (de) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Verbindungen zur immunproteasomhemmung
BR112012025264A2 (pt) 2010-04-07 2019-09-24 Onyx Therapeutics Inc inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN102119912A (zh) * 2011-01-25 2011-07-13 南京白敬宇制药有限责任公司 一种非水溶性药物缓释制剂的制备方法
EP2758052B9 (de) 2011-09-18 2019-03-27 Euro-Celtique S.A. HDAC-Hemmer-Cyclopolysaccharidzusammensetzung
RS59734B1 (sr) 2012-01-23 2020-02-28 Sage Therapeutics Inc Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
JP6508944B2 (ja) 2012-02-15 2019-05-08 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン誘導体のための製造方法
CA2865950C (en) 2012-02-28 2016-12-20 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
MX363455B (es) 2012-07-18 2019-03-25 Onyx Therapeutics Inc Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
NZ705410A (en) 2012-08-21 2018-03-23 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus
EP2909239A4 (de) 2012-10-22 2016-06-08 Cydex Pharmaceuticals Inc Alkylierte zusammensetzungen auf basis von cyclodextrin und verfahren zur herstellung und gebrauch derselben
CN103054882A (zh) * 2012-12-30 2013-04-24 北京阜康仁生物制药科技有限公司 一种以贝奈克酯为活性成分的固体制剂
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
NZ725354A (en) 2014-06-18 2018-05-25 Elanco Us Inc Transdermal formulations of pergolide and uses thereof
DK3183295T3 (da) 2014-08-22 2023-08-21 Cydex Pharmaceuticals Inc Fraktioneret alkyleret cyclodextrinsammensætning og fremgangsmåder til fremstilling og anvendelse af samme
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN104688705B (zh) * 2015-02-09 2017-07-25 武汉泽智生物医药有限公司 一种α‑硫辛酸缓释片及其制备方法
US10569422B2 (en) 2016-01-20 2020-02-25 Soft Robotics, Inc. End of arm tools for soft robotic systems
CN107519181A (zh) * 2016-06-20 2017-12-29 天津金耀集团有限公司 以醋丙甲泼尼龙为活性成分的皮肤药物组合物
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
EP3541364A1 (de) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Neuartige formulierungen von amidinsubstituierten beta-lactam-verbindungen auf basis von modifizierten cyclodextrinen und ansäuerungsmitteln, deren herstellung und verwendung als antimikrobielle pharmazeutische zusammensetzungen
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
JP6870867B2 (ja) * 2017-01-04 2021-05-12 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含有する医薬組成物
JP7204670B2 (ja) * 2017-05-03 2023-01-16 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン及びブスルファンを含有する組成物
CN110612103B (zh) 2017-05-10 2023-08-22 艾克萨姆治疗公司 包含美洛昔康的药物组合物
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
WO2019051477A1 (en) 2017-09-11 2019-03-14 Sage Therapeutics, Inc. METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
US11072080B2 (en) * 2017-11-10 2021-07-27 Soft Robotics, Inc. End of arm tools for soft robotic systems
JP2021502263A (ja) * 2017-11-10 2021-01-28 ソフト ロボティクス， インコーポレイテッド ソフトロボットシステム用のアームの端部ツール
DE102017127452A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag Wasserlösliche Polymerklebschichten
ES2914305T3 (es) * 2017-12-26 2022-06-09 Ind Tech Res Inst Composición para mejorar la solubilidad de sustancias poco solubles, uso de la misma y formulación compleja que contiene la misma
EP4010031A1 (de) 2019-08-06 2022-06-15 L.E.A.F Holdings Group LLC Verfahren zur herstellung von polyglutamat-antifolaten und ihre verwendungen
US20230227506A1 (en) 2020-06-18 2023-07-20 The University Of Bristol Fatty Acid Complexes Of Coronavirus Spike Protein And Their Use
EP4243805A1 (de) 2020-08-07 2023-09-20 Gbiotech S.À.R.L. Kombinationstherapien zur behandlung von coronavirusinfektion
WO2023073513A1 (en) * 2021-10-26 2023-05-04 Alembic Pharmaceuticals Limited Pharmaceutical composition containing combination of meloxicam and rizatriptan and process of preparation thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
JPS58172311A (ja) * 1982-04-02 1983-10-11 Kodama Kk 持続性製剤及びその製法
JPS5984821A (ja) * 1982-11-04 1984-05-16 Teikoku Chem Ind Corp Ltd 徐溶化組成物
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPS62149628A (ja) * 1985-12-24 1987-07-03 Michio Nakanishi 抗生物質含有医薬組成物
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
JPS6440567A (en) * 1987-08-05 1989-02-10 Chikahisa Shoten Kk Clathrate product
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
WO1994014421A2 (en) * 1992-12-23 1994-07-07 Saitec S.R.L. Process for preparing controlled release pharmaceutical forms and the forms thus obtained
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
DE19513659A1 (de) * 1995-03-10 1996-09-12 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use

Also Published As

Publication number Publication date
PT1140960E (pt) 2007-11-29
EP1859790A2 (de) 2007-11-28
ES2290012T3 (es) 2008-02-16
AU2501100A (en) 2000-08-01
RU2233176C2 (ru) 2004-07-27
RU2233176C9 (ru) 2006-02-10
EP1859790A3 (de) 2008-03-05
MXPA01007122A (es) 2003-07-21
CA2360236A1 (en) 2000-07-20
JP2006316076A (ja) 2006-11-24
CA2360236C (en) 2009-04-28
AU758376B2 (en) 2003-03-20
DE60036534T2 (de) 2009-01-29
ATE374017T1 (de) 2007-10-15
EP1897559A1 (de) 2008-03-12
KR100712941B1 (ko) 2007-05-02
US6046177A (en) 2000-04-04
EP1897560A1 (de) 2008-03-12
CN1202833C (zh) 2005-05-25
EP1140960A1 (de) 2001-10-10
HK1049797A1 (en) 2003-05-30
EP1140960A4 (de) 2003-03-26
EP1140960B1 (de) 2007-09-26
JP2002534472A (ja) 2002-10-15
WO2000041704A1 (en) 2000-07-20
IL143900A0 (en) 2002-04-21
CN1370072A (zh) 2002-09-18
KR20050092056A (ko) 2005-09-16
NZ512692A (en) 2002-10-25
IL143900A (en) 2008-11-26
KR20010101481A (ko) 2001-11-14

Similar Documents

Publication Publication Date Title
DE60036534D1 (de) Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung
PT1283700E (pt) Composicoes farmaceuticas de libertacao prolongada destinadas a administracao por via parental de compostos hidrofilos biologicamente activos
BR0107621A (pt) Sistema de liberação de droga por bombeamento osmótico/ difusão combinados
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
IS6344A (is) Lyfjasamsetningar sem leiða til aukinna lyfjastyrkja
CA2396152A1 (en) Osmotic device within an osmotic device
SE9902386D0 (sv) New formulation
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
ATE313319T1 (de) Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe
AU4868297A (en) Water soluble film for oral administration with instant wettability
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
ATE238813T1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
PT90341A (pt) Processo para a preparacao de um sistema de fornecimento oral de distribuicao continua osmotica, contendo metoprolol como agente activo farmaceuticamente aceitavel, tendo melhores propriedades de adesao da membrana do nucleo
DE60129849D1 (de) Bioadhäsiver schaumstoffilm mit hinhaltender wirkstoffreigabe
DK1171101T3 (da) Fremgangsmåde til fremstilling af en vanduoplöselig amorf depotmatrix
ATE469644T1 (de) Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
DE50114127D1 (de) Torasemid enthaltende lagerstabile pharmazeutische zubereitungen
TN2010000008A1 (en) Oral pharmaceutical solutions containing telbivudine
DE60004204D1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
ATE158172T1 (de) Pulverförmige pharmazeutische zusammensetzung
WO2003096968A3 (en) Oral osmotic controlled drug delivery system
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
DE502004001894D1 (de) Pharmazeutische Zubereitungen mit amorphem Tibolon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CYDEX PHARMACEUTICALS, INC., LENEXA, KAN., US